1. Stopping Hospital Infections With Environmental Services (SHINE): A Cluster-randomized Trial of Intensive Monitoring Methods for Terminal Room Cleaning on Rates of Multidrug-resistant Organisms in the Intensive Care Unit.
- Author
-
Ziegler MJ, Babcock HH, Welbel SF, Warren DK, Trick WE, Tolomeo P, Omorogbe J, Garcia D, Habrock-Bach T, Donceras O, Gaynes S, Cressman L, Burnham JP, Bilker W, Reddy SC, Pegues D, Lautenbach E, Kelly BJ, Fuchs B, Martin ND, and Han JH
- Subjects
- Adenosine Triphosphate, Drug Resistance, Multiple, Bacterial, Gram-Negative Bacteria, Humans, Intensive Care Units, Vancomycin, Cross Infection epidemiology, Cross Infection prevention & control, Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococci
- Abstract
Background: Multidrug-resistant organisms (MDROs) frequently contaminate hospital environments. We performed a multicenter, cluster-randomized, crossover trial of 2 methods for monitoring of terminal cleaning effectiveness., Methods: Six intensive care units (ICUs) at 3 medical centers received both interventions sequentially, in randomized order. Ten surfaces were surveyed each in 5 rooms weekly, after terminal cleaning, with adenosine triphosphate (ATP) monitoring or an ultraviolet fluorescent marker (UV/F). Results were delivered to environmental services staff in real time with failing surfaces recleaned. We measured monthly rates of MDRO infection or colonization, including methicillin-resistant Staphylococcus aureus, Clostridioides difficile, vancomycin-resistant Enterococcus, and MDR gram-negative bacilli (MDR-GNB) during a 12-month baseline period and sequential 6-month intervention periods, separated by a 2-month washout. Primary analysis compared only the randomized intervention periods, whereas secondary analysis included the baseline., Results: The ATP method was associated with a reduction in incidence rate of MDRO infection or colonization compared with the UV/F period (incidence rate ratio [IRR] 0.876; 95% confidence interval [CI], 0.807-0.951; P = .002). Including the baseline period, the ATP method was associated with reduced infection with MDROs (IRR 0.924; 95% CI, 0.855-0.998; P = .04), and MDR-GNB infection or colonization (IRR 0.856; 95% CI, 0.825-0.887; P < .001). The UV/F intervention was not associated with a statistically significant impact on these outcomes. Room turnaround time increased by a median of 1 minute with the ATP intervention and 4.5 minutes with UV/F compared with baseline., Conclusions: Intensive monitoring of ICU terminal room cleaning with an ATP modality is associated with a reduction of MDRO infection and colonization., Competing Interests: Potential conflicts of interest. D. K. W. reports payment for consulting made to self from Mölnlycke Health Care AB, Homburg & Partner, and Pursuit Vascular, Inc. H. M. B. reports payment for expert testimony from ACLU for testifying in support of mail-in voting during the pandemic; support for attending meetings and/or travel from SHEA; and leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid from SHEA and HICPAC (CDC). J. H. reports holding shares in and being employee of GSK group of companies. M. Z. reports grants or contracts from the National Institutes for Health (NIH) outside of the submitted work. O. T. D. reports receipt of equipment, materials, drugs, medical writing, gifts, or other services from ATP bioluminescence and UV/F marker. S. F. W. reports grants or contracts from the Centers for Disease Control and Prevention outside of the submitted work and receipt for equipment, materials, drugs, medical writing, gifts, or other services from ATP bioluminescence and UV/F marker. W. E. T. reports being Treasurer as a volunteer board member for Medical Research Analytics and Informatics Alliance. All other authors report no conflicts of interest relevant to this study. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF